Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion

Precision medicine for infantile fibrosarcoma by monitoring of spatial and temporal clonal evolution (requested from authors: Would you be so kind to let us know when the article is announced via Twitter?).

[1]  F. Jardin,et al.  Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors , 2021, The American journal of surgical pathology.

[2]  Shou-ping Gong,et al.  Whole Exome Sequencing of Multiple Atypical Meningiomas in a Patient without History of Neurofibromatosis Type II: A Case Report , 2020, The American journal of case reports.

[3]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[4]  Kathleen R. Cho,et al.  Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. , 2020, The Journal of clinical investigation.

[5]  S. DuBois,et al.  The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers , 2020, Pediatric Drugs.

[6]  F. Speleman,et al.  The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review , 2020, European Journal of Pediatrics.

[7]  Kristian Cibulskis,et al.  Calling Somatic SNVs and Indels with Mutect2 , 2019, bioRxiv.

[8]  S. Bielack,et al.  The Impact of Local Control in the Treatment of Children with Advanced Infantile and Adult-Type Fibrosarcoma: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS). , 2019, Journal of pediatric surgery.

[9]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[10]  Jessica L. Davis,et al.  The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas , 2018, Cancer.

[11]  D. Hong,et al.  Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins , 2018, Clinical Cancer Research.

[12]  Jessica L. Davis,et al.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.

[13]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[14]  B. Taylor,et al.  A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.

[15]  Gavin R. Oliver,et al.  Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma , 2017, Rare tumors.

[16]  Vikas Prasad,et al.  2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors , 2017, Klinische Pädiatrie.

[17]  F. Meric-Bernstam,et al.  Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.

[18]  Paul Flicek,et al.  The international Genome sample resource (IGSR): A worldwide collection of genome variation incorporating the 1000 Genomes Project data , 2016, Nucleic Acids Res..

[19]  J. Wolinsky,et al.  Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA , 2016, Cancer.

[20]  K. Okkenhaug,et al.  PI3Kδ and primary immunodeficiencies , 2016, Nature Reviews Immunology.

[21]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[22]  Maged El-Setouhy,et al.  Exome sequencing of oral squamous cell carcinoma in users of Arabian snuff reveals novel candidates for driver genes , 2016, International journal of cancer.

[23]  U. Dirksen,et al.  Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.

[24]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[25]  M. Ladanyi,et al.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Shaomin Li,et al.  Sequencing study on familial lung squamous cancer. , 2015, Oncology letters.

[27]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[28]  Sahar Mansour,et al.  Mutations in PIK3R1 cause SHORT syndrome. , 2013, American journal of human genetics.

[29]  G. Crabtree,et al.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy , 2013, Nature Genetics.

[30]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[31]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[32]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[33]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[34]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[35]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[36]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[37]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[38]  T. O'Halloran,et al.  A novel role for clathrin in cytokinesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.